Breaks Categories: News

TuesdayMar 19, 2024 12:29 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive agreements for the sale and issuance of 1,542,112 shares of its common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant, in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $4.09 per…

Continue Reading

TuesdayMar 19, 2024 12:07 pm

BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. Hosted by Vial EVP Rich McCormick, the podcast is available for on-demand listening on First in Human by Vial. Rob Etherington, president, director and CEO of Clene joined the program to highlight information about the company’s work in the field of nanotechnology. “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the…

Continue Reading

FridayMar 15, 2024 11:34 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced the publication of peer-reviewed research, titled “Protein Corona Composition of Gold Nanocrystals.” The publication appeared in the journal ACS Pharmacology & Translational Science and fully characterized the proteins from human blood plasma that form the protein corona of the gold nanocrystals of CNM-Au8(R), Clene’s investigational drug in development for the treatment of neurodegenerative diseases. “The protein corona of CNM-Au8 gold nanocrystals, tailored for brain delivery…

Continue Reading

FridayMar 15, 2024 10:27 am

BioMedNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering

Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company developing product candidates designed to treat neurodegenerative disorders, has closed on its previously announced underwritten public offering. The offering was comprised of 6,571,428 shares of its common stock. According to the announcement, each share of common stock was sold at $1.75 per share, resulting in approximately $11.5 million in gross proceeds before deductions, commissions and expenses. Cognition Therapeutics anticipates using the funds from the offering for research, clinical development, process development and manufacturing, working capital, capital expenditures and other general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as…

Continue Reading

ThursdayMar 14, 2024 3:15 pm

BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study

BioNxt (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) has announced completion of the comparative pharmacokinetic (“PK”) study for its oral dissolvable film (“ODF”) based proprietary Cladribine product for the treatment of multiple sclerosis (“MS”). The company reported that the animal PK study results are highly promising and demonstrated comparable rapid absorption and systemic exposure between BioNxt’s ODF product and the name-brand reference drug in all samples. “These results are a significant milestone for BioNxt. We have demonstrated that our ODF platform is an effective drug delivery system for cytostatic drugs via transmucosal absorption,” said BioNxt CEO Hugh Rogers. “With our recently…

Continue Reading

ThursdayMar 14, 2024 2:38 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in Key Study Assessing Proprietary AIMIGo(TM) System

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, Georgia. HeartBeam anticipates the VALID-ECG study will form the basis of its planned FDA 510(k) submission. The study is designed to evaluate the performance of a 12-lead ECG synthesized from the credit-card-sized HeartBeam AIMIGo(TM) system compared to a standard hospital-based 12-lead ECG; the study will use both quantitative and qualitative methodologies…

Continue Reading

WednesdayMar 13, 2024 4:17 pm

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Names Seasoned Financial Expert as New CFO

HealthLynked (OTCQB: HLYK), a pioneering provider of healthcare network and services, has appointed David Rosal as its new chief financial officer, effective March 18, 2024. Rosal has worked at both McDonald’s Corporation and Teradata, accumulating more than two decades of experience in financial planning, business scaling and strategic development. At McDonald’s, Rosal was instrumental in scaling the business, and his leadership was key to the company's growth and operational efficiency across multiple locations. His insight and expertise from this background is “directly relevant to HealthLynked's mission to expand its in-network physician and healthcare service network,” noted the company, which is…

Continue Reading

WednesdayMar 13, 2024 4:11 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Shares Vision, Innovations in ASD Treatments in Updated Company Presentation

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in autism spectrum disorder (“ASD”) therapeutics, and its commitment to addressing unmet needs within the ASD community. “PaxMedica is pleased to share our vision and progress with the wider community,” said Howard Weisman, chairman and CEO of PaxMedica. “We believe that our work has the potential to transform the treatment landscape for ASD, offering a new horizon of hope and support for affected individuals and their loved ones.” To…

Continue Reading

WednesdayMar 13, 2024 12:18 pm

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced its full year 2023 financial results. In addition, the company provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “In 2024 we will continue to advance our regulatory discussions with the U.S. Food and Drug Administration (‘FDA’) that we anticipate will include new data on biomarkers, as well as additional clinical function and survival data in people…

Continue Reading

TuesdayMar 12, 2024 1:58 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month’s BIO-Europe Spring 2024 conference. The conference is scheduled for March 18–20, 2024, in Barcelona. According to the announcement, Scinai management will be attending the event and will be available for discussions with prospective clients, potential pharma partners that may be interested in co-advancing or in-licensing Scinai's innovative NanoAb for the treatment of mild to moderate plaque psoriasis, and institutional and private investors. In addition, the company is hosting a booth…

Continue Reading